Serum Protein Signatures Using Aptamer-Based Proteomics for Minimal Change Disease and Membranous Nephropathy

• Published in: Kidney international reports Vol. 7; no. 7; pp. 1539 - 1556
• Main Authors: Muruve, Daniel A., Debiec, Hanna, Dillon, Simon T., Gu, Xuesong, Plaisier, Emmanuelle, Can, Handan, Otu, Hasan H., Libermann, Towia A., Ronco, Pierre
• Format: Journal Article
• Language: English
• Published: Elsevier Inc 01.07.2022; Elsevier
• Subjects: Clinical Research; Human health and pathology; Life Sciences; membranous nephropathy; minimal change disease; proteomics; systems biology; Urology and Nephrology; systems biology; minimal change disease; proteomics; membranous nephropathy
• ISSN: 2468-0249; 2468-0249
• DOI: 10.1016/j.ekir.2022.04.006

Minimal change disease (MCD) and membranous nephropathy (MN) are glomerular diseases (glomerulonephritis [GN]) that present with the nephrotic syndrome. Although circulating PLA2R antibodies have been validated as a biomarker for MN, the diagnosis of MCD and PLA2R-negative MN still relies on the results of kidney biopsy or empirical corticosteroids in children. We aimed to identify serum protein biomarker signatures associated with MCD and MN pathogenesis using aptamer-based proteomics. Quantitative SOMAscan proteomics was applied to the serum of adult patients with MCD (n = 15) and MN (n = 37) and healthy controls (n = 20). Associations between the 1305 proteins detected with SOMAscan were assessed using multiple statistical tests, expression pattern analysis, and systems biology analysis. A total of 208 and 244 proteins were identified that differentiated MCD and MN, respectively, with high statistical significance from the healthy controls (Benjamin-Hochberg [BH] P < 0.0001). There were 157 proteins that discriminated MN from MCD (BH P < 0.05). In MCD, 65 proteins were differentially expressed as compared with MN and healthy controls. When compared with MCD and healthy controls, 44 discriminatory proteins were specifically linked to MN. Systems biology analysis of these signatures identified cell death and inflammation as key pathways differentiating MN from MCD and healthy controls. Dysregulation of fatty acid metabolism pathways was confirmed in both MN and MCD as compared with the healthy subjects. SOMAscan represents a promising proteomic platform for biomarker development in GN. Validation of a greater number of discovery biomarkers in larger patient cohorts is needed before these data can be translated for clinical care.